Compare FLNA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLNA | COCH |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | United States | United States |
| Employees | 20 | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | FLNA | COCH |
|---|---|---|
| Price | $1.25 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 346.0K | 123.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $0.36 |
| 52 Week High | $2.03 | $1.89 |
| Indicator | FLNA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 41.74 |
| Support Level | $1.16 | $0.64 |
| Resistance Level | $1.80 | $0.73 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 4.41 | 25.58 |
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.